RecruitingPhase 2NCT07751159

Radiation Therapy Approaches for People With Prostate Cancer

Balancing Radiation Intensification and Quality of Life in Higher-Risk Prostate Cancer (The BALANCE-RT Trial)

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

126 participants

Start Date

Jul 31, 2026

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer Patients High-risk Prostate Cancer Non-metastatic Prostate Cancer

Summary

The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Brachytherapy and a drug called SBRT for people with high-risk prostate cancer, non-metastatic prostate cancer, and other related conditions. The study is currently recruiting participants at 7 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONStandard of Care HDR Brachytherapy

HDR Brachytherapy

RADIATIONSBRT

SBRT alone

Locations(7)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering at Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

Commack, New York, United States

Memorial Sloan Kettering at Westchester (Limited Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

New York, New York, United States

Memorial Sloan Kettering at Nassau (Limited Protocol Activities)

Uniondale, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07751159

Related Trials

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

NCT070543461 location

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

NCT055934976 locations

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

NCT062022481 location

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

NCT070271241 location

Cancer Survivors Program

NCT072539871 location